咪唑斯汀 | 108612-45-9

• 物质功能分类: 原料药 - 抗肿瘤药 - 烷化剂类抗肿瘤药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 咪唑斯汀
• 中文别名: 咪唑司汀；2-[[1-[1-[(4-氟苯基)甲基]苯并咪唑-2-基]-4-哌啶基]-甲基氨基]-3H-嘧啶-4-酮
• 英文名称: mizolastine
• 英文别名: 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]pyrimidin-4-ol
• CAS: 108612-45-9
• 化学式: C₂₄H₂₅FN₆O
• mdl: MFCD00864625
• 分子量: 432.501
• InChiKey: PVLJETXTTWAYEW-UHFFFAOYSA-N

物化性质

• 熔点：
  217°
• 密度：
  1.34±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（略微加热）、DMSO、甲醇（略微加热）

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.291
• 拓扑面积：
  65.8
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• RTECS号：
  UW7481284
• 海关编码：
  2933990090
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Mizolastine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Mizolastine
CAS number: 108612-45-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C24H25FN6O
Molecular weight: 432.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

荨麻疹治疗药——咪唑司汀是一种抗组胺药，又称为咪唑斯汀。它不仅具有较强的抗组胺作用，还能够抑制其他炎症递质的产生，如白三烯等，从而减轻水肿。因此，从理论上讲，咪唑司汀既具备抗组胺、抗过敏的效果，又有抗炎活性，是急性荨麻疹治疗的优选药物。与其它抗组胺药相比，它的起效更快，用药1～3小时后风团数量会明显减少，瘙痒程度也会减轻，并且维持时间长，可达24小时。

目前临床上主要使用咪唑司汀来治疗成人或12岁以上的儿童所患的荨麻疹等皮肤过敏症状、季节性过敏性鼻炎（花粉症）及常年性过敏性鼻炎。

生物活性 Mizolastine (SL 850324) 是一种组胺H1受体拮抗剂，其IC50值为47 nM。它用于治疗花粉症（季节性过敏性鼻炎）、荨麻疹和其他过敏反应。

靶点

Target	Value
Histamine H1 receptor	47 nM

用途 治疗慢性过敏性鼻炎

反应信息

• 作为反应物：
  描述：

  辛酸碘甲酯 、 咪唑斯汀 在 正丁基锂 作用下， 以 正己烷 、 四氢呋喃 为溶剂， 反应 17.0h， 以17%的产率得到(2-(N-(1-(1-(4-fluorobenzyl)-1 H-benzo[d]imidazol2-yl)piperidin-4-yl)-N-methylamino)-6-oxopyrimi-din-i (6H)-yl)methyl octanoate
  参考文献：
  名称：

  Prodrugs of NH-acidic compounds

  摘要：

  该发明提供了一种持续释放内酰胺、亚酰胺、酰胺、磺胺、氨基甲酸酯或尿素含有母体药物的方法，通过向患者施用本发明的一种前药化合物的有效量，在患者体内，从前药中释放母体药物是持续释放的。适用于本发明方法的前药化合物是母体药物的不稳定结合物，通过羰基连接的前药基团进行衍生化。本发明的前药化合物可用于治疗任何需要内酰胺、亚酰胺、酰胺、磺胺、氨基甲酸酯或尿素含有母体药物作为治疗的情况。

  公开号：

  US09102618B2
• 作为产物：
  描述：

  2-({1-[1-(4-fluorobenzyl)-1H-benzimidazol-2-yl]-piperidin-4-yl}-aminomethyl)-4-benzyloxypyrimidine 在 氢溴酸 、 sodium hydroxide 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 反应 12.0h， 生成 咪唑斯汀
  参考文献：
  名称：

  PROCESS AND INTERMEDIATES FOR OBTAINING 1-(1H-BENZIMIDAZOL-2-YL)-4-(PYRIMIDIN-2-YLAMINO)PIPERIDINE DERIVATIVES

  摘要：

  公开号：

  EP1564212B1

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] FUSED PYRAZOLE DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLE CONDENSÉS UTILISÉS EN TANT QU'INHIBITEURS DE JAK
  申请人：ALMIRALL SA

  公开号：WO2017220431A1

  公开（公告）日：2017-12-28

  Novel fused pyrazole derivatives of Formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

  公开了式（I）的新型融合吡唑衍生物；以及它们的制备方法，包含它们的药物组合物以及它们作为Janus激酶（JAK）抑制剂在治疗中的用途。
• [EN] PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINONE EN TANT QU'INHIBITEURS DES PI3K
  申请人：ALMIRALL SA

  公开号：WO2014060432A1

  公开（公告）日：2014-04-24

  New pyrrolotriazinone derivatives having the chemical structure of formula (I), are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)

  新的吡咯三唑酮衍生物具有化学结构式（I），公开；以及它们的制备方法，包括它们的药物组合物和它们作为磷脂酰肌醇3-激酶（PI3Ks）抑制剂在治疗中的应用。
• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20190192668A1

  公开（公告）日：2019-06-27

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• Imidazole and benzimidazole derivatives useful as histamine H3 antagonists
  申请人：Aslanian G. Robert

  公开号：US20060166960A1

  公开（公告）日：2006-07-27

  Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: n is 2-5; R is R 3 -aryl, R 3 -heteroaryl, R 3 -cycloalkyl, R 3 -heterocycloalkyl, alkyl, haloalkyl, —OR 4 , —SR 4 or —S(O) 1-2 R 5 ; R 1 and R 2 are H or optionally substituted phenyl or optionally substituted and X is —O— or —S—; or R 1 and R 2 , together with the carbon atoms to which they are attached form optionally substituted and X is —O—, —S— or —NR 7 —; Z is and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I; also disclosed are methods of treating allergy, allergy-induced airway responses, congestion, obesity and metabolic syndrome using the compounds of Formula I, as well as combinations with other drugs useful for treating those diseases.

  揭示了以下公式化合物或其药学上可接受的盐或溶剂，其中：n为2-5；R为R3-芳基，R3-杂环芳基，R3-环烷基，R3-杂环烷基，烷基，卤代烷基，—OR4，—SR4或—S(O)1-2R5；R1和R2为H或可选择地取代的苯基或可选择地取代的，X为—O—或—S—；或R1和R2，连同它们连接的碳原子形成可选择地取代的，X为—O—，—S—或—NR7—；Z为，其余变量如规范中所定义；还揭示了包括公式I化合物的药物组合物；还揭示了使用公式I化合物治疗过敏、过敏引起的气道反应、充血、肥胖和代谢综合征的方法，以及与其他用于治疗这些疾病的药物的组合。